Universitäts-Kinderspital beider Basel UKBB
Welcome,         Profile    Billing    Logout  
 1 Trial 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hartmann, Karin
HARBOR, NCT04910685 / 2020-005173-28: () Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Recruiting
2/3
463
Europe, US, RoW
Elenestinib, BLU-263, Placebo
Blueprint Medicines Corporation
Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, Smoldering Systemic Mastocytosis
06/28
06/28
ENABLE, NCT04130191: A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II

Completed
N/A
140
Europe, RoW
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE)
09/24
09/24
NCT05819463: Treatment and Medical Care of Patients with Moderate-to-severe Atopic Dermatitis - TREATswitzerland

Recruiting
N/A
700
Europe
Swiss Society of Dermatology and Venereology
Atopic Dermatitis
05/32
12/32
Woerner, Andreas
NCT04527380 / 2018-000681-10: A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Active, not recruiting
3
100
Europe, RoW
Ixekizumab, LY2439821, Adalimumab
Eli Lilly and Company
Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
02/24
04/28

Download Options